Idexx Laboratories share price today

(IDXX)

Idexx Laboratories share price is $444.72 & ₹37,704.70 as on 11 Dec 2024, 2.30 'hrs' IST

$444.72

▲

-5.96

(-1.32%)

Market is closed - opens 8 PM, 11 Dec 2024

View live Idexx Laboratories share price in Dollar and Rupees. Guide to invest in Idexx Laboratories from India. Also see the sentimental analysis on Indian investors investing in Idexx Laboratories. Get details on the Indian mutual funds that are investing in Idexx Laboratories. Get Analyst recommendations and forecasts along with all the Idexx Laboratories's financials.

Idexx Laboratories Key Statistics

in dollars & INR

Previous Close	$450.68
Open	$450.38
Today's High	$451.29
Today's Low	$442.37
Market Capitalization	$36.9B
Today's Volume	$675.4K
Revenue TTM	$3.8B
EBITDA	$1.3B
Earnings Per Share (EPS)	$10.36
PE Ratio	42.93
Profit Margin	22.53%
Quarterly Earnings Growth YOY	0.11%
Return On Equity TTM	59.42%

How to invest in Idexx Laboratories from India?

It is very easy for Indian residents to invest directly in Idexx Laboratories from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Idexx Laboratories stock in both rupees (INR) and dollars (USD). Search for Idexx Laboratories or IDXX on INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Idexx Laboratories or Rupee/ Dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Idexx Laboratories shares which would translate to 0.002 fractional shares of Idexx Laboratories as of today. Learn more about fractional investing here.

Indians via INDmoney can now also, easily transfer and add their money to the US stocks account via INDmoney App. Click here for step by step process for the same

Indian investors sentiment towards Idexx Laboratories

-35%

Period: Sep 11, 2024 to Dec 10, 2024. Change in 30 Days versus previous period

Search volume for Idexx Laboratories on INDmoney from India has reduced in the last 30 days as on Dec 11, 2024. -35% less investors are searching Idexx Laboratories in the last 30 days versus the previous period.

Indian Mutual Funds that own Idexx Laboratories

Name	Shares Held	Change in Shares	% of Assets
Motilal Oswal S&P 500 Index Fund Direct Growth	707	-11.29	0.07%
ICICI Prudential NASDAQ 100 Index Fund Direct Growth	1066	-54.88	0.22%

Global Institutional Holdings in Idexx Laboratories

Vanguard Group Inc
11.85%
BlackRock Inc
11.73%
State Street Corp
4.41%
AllianceBernstein L.P.
3.44%
Fundsmith LLP
3.25%
Geode Capital Management, LLC
2.76%

Analyst Recommendation on Idexx Laboratories

Buy

68%Buy

31%Hold

0%Sell

Based on 19 Wall street analysts offering stock ratings for Idexx Laboratories(by analysts ranked 0 to 5 stars)

Based on 19 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Idexx Laboratories

What analysts predicted

Upside of 7.61%

Current:

$444.72

Target:

$478.55

Insights on Idexx Laboratories

Price Movement
In the last 7 days, IDXX stock has moved up by 2.4%
Decreasing Revenue
Idexx Laboratories, Inc. has experienced a decline in revenue over the past two quarters. The revenue decreased from $1.00 billion to $975.54 million, resulting in an average decrease of 2.8% per quarter.
Increasing Net Profit
Idexx Laboratories, Inc. has shown a positive profit trend over the last two quarters. The net profit increased from $203.29 million to $232.84 million, resulting in an average increase of 12.7% per quarter.
IDXX vs A (1 yr)
In the last 1 year, Agilent Technologies Inc. has given 10.0% return, outperforming this stock by 27.0%
IDXX vs A (3 yr)
In the last 3 years, Idexx Laboratories, Inc. has experienced a drawdown of -26.8%, however Agilent Technologies Inc. resisted the overall trend and outperformed by 17.6%
Price to Sales
Idexx Laboratories, Inc. has a Price-to-Sales Ratio of 9.6, meaning that investors are willing to pay $9.6 for every $1 of sales the company generates. In comparison, investors pay $6.4 for every $1 of sales for Agilent Technologies Inc. This indicates that investors value Idexx Laboratories more highly relative to its sales than they do Agilent Technologies.

Idexx Laboratories Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$2.2B	↑ 12.4%
Net Income	$377.0M	↑ 43.28%
Net Profit Margin	17.04%	↑ 3.68%

	FY19	Y/Y Change
Revenue	$2.4B	↑ 8.75%
Net Income	$427.7M	↑ 13.44%
Net Profit Margin	17.77%	↑ 0.73%

	FY20	Y/Y Change
Revenue	$2.7B	↑ 12.45%
Net Income	$581.8M	↑ 36.02%
Net Profit Margin	21.49%	↑ 3.72%

	FY21	Y/Y Change
Revenue	$3.2B	↑ 18.79%
Net Income	$744.8M	↑ 28.03%
Net Profit Margin	23.17%	↑ 1.68%

	FY22	Y/Y Change
Revenue	$3.4B	↑ 4.73%
Net Income	$679.1M	↓ 8.83%
Net Profit Margin	20.17%	↓ 3.0%

	FY23	Y/Y Change
Revenue	$3.7B	↑ 8.72%
Net Income	$845.0M	↑ 24.44%
Net Profit Margin	23.08%	↑ 2.91%

	Q2 FY23	Q/Q Change
Revenue	$943.6M	↑ 4.83%
Net Income	$224.2M	↑ 4.76%
Net Profit Margin	23.76%	↓ 0.02%

	Q3 FY23	Q/Q Change
Revenue	$915.5M	↓ 2.98%
Net Income	$212.2M	↓ 5.35%
Net Profit Margin	23.18%	↓ 0.58%

	Q4 FY23	Q/Q Change
Revenue	$901.6M	↓ 1.52%
Net Income	$194.5M	↓ 8.34%
Net Profit Margin	21.58%	↓ 1.6%

	Q1 FY24	Q/Q Change
Revenue	$964.1M	↑ 6.93%
Net Income	$235.6M	↑ 21.11%
Net Profit Margin	24.44%	↑ 2.86%

	Q2 FY24	Q/Q Change
Revenue	$1.0B	↑ 4.1%
Net Income	$203.3M	↓ 13.7%
Net Profit Margin	20.26%	↓ 4.18%

	Q3 FY24	Q/Q Change
Revenue	$975.5M	↓ 2.79%
Net Income	$232.8M	↑ 14.53%
Net Profit Margin	23.87%	↑ 3.61%

	FY18	Y/Y Change
Total Assets	$1.5B	↓ 10.28%
Total Liabilities	$1.5B	↓ 12.49%

	FY19	Y/Y Change
Total Assets	$1.8B	↑ 19.2%
Total Liabilities	$1.7B	↑ 6.99%

	FY20	Y/Y Change
Total Assets	$2.3B	↑ 25.22%
Total Liabilities	$1.7B	↑ 0.43%

	FY21	Y/Y Change
Total Assets	$2.4B	↑ 6.22%
Total Liabilities	$1.7B	↑ 5.14%

	FY22	Y/Y Change
Total Assets	$2.7B	↑ 12.7%
Total Liabilities	$2.1B	↑ 22.37%

	FY23	Y/Y Change
Total Assets	$3.3B	↑ 18.68%
Total Liabilities	$1.8B	↓ 16.96%

	Q2 FY23	Q/Q Change
Total Assets	$2.9B	↑ 2.22%
Total Liabilities	$1.8B	↓ 9.68%

	Q3 FY23	Q/Q Change
Total Assets	$3.1B	↑ 7.51%
Total Liabilities	$1.8B	↑ 0.68%

	Q4 FY23	Q/Q Change
Total Assets	$3.3B	↑ 5.62%
Total Liabilities	$1.8B	↓ 0.76%

	Q1 FY24	Q/Q Change
Total Assets	$3.4B	↑ 2.87%
Total Liabilities	$1.8B	↑ 0.52%

	Q2 FY24	Q/Q Change
Total Assets	$3.4B	↑ 1.83%
Total Liabilities	$1.8B	↑ 2.8%

	Q3 FY24	Q/Q Change
Total Assets	$3.4B	↓ 1.88%
Total Liabilities	$1.7B	↓ 5.55%

	FY18	Y/Y Change
Operating Cash Flow	$400.1M	↑ 7.18%
Investing Cash Flow	$138.6M	↓ 199.94%
Financing Cash Flow	$-597.8M	↑ 187.38%

	FY19	Y/Y Change
Operating Cash Flow	$459.2M	↑ 14.77%
Investing Cash Flow	$-205.5M	↓ 248.29%
Financing Cash Flow	$-286.4M	↓ 52.09%

	FY20	Y/Y Change
Operating Cash Flow	$648.1M	↑ 41.14%
Investing Cash Flow	$-109.4M	↓ 46.78%
Financing Cash Flow	$-248.4M	↓ 13.27%

	FY21	Y/Y Change
Operating Cash Flow	$755.5M	↑ 16.59%
Investing Cash Flow	$-293.0M	↑ 167.85%
Financing Cash Flow	$-697.4M	↑ 180.74%

	FY22	Y/Y Change
Operating Cash Flow	$543.0M	↓ 28.13%
Investing Cash Flow	$-195.4M	↓ 33.32%
Financing Cash Flow	$-370.9M	↓ 46.81%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$200.3M	↑ 8.92%
Investing Cash Flow	$-27.5M	↓ 30.48%
Financing Cash Flow	$-151.0M	↑ 3.39%

Idexx Laboratories Technicals Summary

Sell

Neutral

Buy

Idexx Laboratories is currently in a neutral trading position according to technical analysis indicators.

Idexx Laboratories Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Idexx Laboratories, Inc.	1.7%	-13.53%	-18.41%	-26.53%	75.85%
Agilent Technologies Inc.	6.03%	6.59%	10.2%	-9.19%	69.55%
Thermo Fisher Scientific, Inc.	-2.02%	-6.92%	7.74%	-17.05%	67.19%
Danaher Corp.	-3.66%	-11.44%	6.64%	-26.43%	57.78%
Iqvia Holdings Inc.	-6.36%	-6.56%	-6.54%	-24.67%	40.28%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Idexx Laboratories, Inc.	42.93	42.93	4.74	10.73	0.59	0.23	NA	19.72
Agilent Technologies Inc.	31.62	31.97	2.44	5.24	0.25	0.08	0.01	20.53
Thermo Fisher Scientific, Inc.	32.68	33.55	2.05	21.7	0.13	0.05	0.0	128.08
Danaher Corp.	44.22	44.22	3.15	7.5	0.08	0.04	0.0	71.03
Iqvia Holdings Inc.	26.66	26.66	1.05	11.12	0.22	0.05	NA	38.37

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Idexx Laboratories, Inc.	Buy	$36.9B	75.85%	42.93	22.53%
Agilent Technologies Inc.	Buy	$40.0B	69.55%	31.62	21.75%
Thermo Fisher Scientific, Inc.	Buy	$199.2B	67.19%	32.68	14.48%
Danaher Corp.	Buy	$170.4B	57.78%	44.22	16.39%
Iqvia Holdings Inc.	Buy	$36.9B	40.28%	26.66	9.17%

About Idexx Laboratories

idexx laboratories, inc. (nasdaq: idxx) is a leader in pet healthcare innovation, serving practicing veterinarians around the world with a broad range of diagnostic and information technology-based products and services. headquartered in southern maine, idexx conducts operations through more than 70 locations around the world, serves customers in over 175 countries, and employs more than 6,000 people. idexx's primary business focuses on pet health, a growing market around the world. idexx products —in-clinic diagnostic tests and instrumentation, reference laboratory and telemedicine consultation services, and practice management software—enhance the ability of veterinarians to provide advanced medical care, improve staff efficiency and to build more economically successful practices. idexx also develops and manufactures diagnostic tests and information for the global production animal industry, including poultry and livestock, as well as tests for the quality and safety of water an

Organization	Idexx Laboratories
Employees	11000
CEO	Mr. Jonathan J. Mazelsky
Industry	Health Technology

Management People of Idexx Laboratories

Name	Title
Mr. Jonathan J. Mazelsky	President, CEO & Director
Mr. Brian P. McKeon	CFO, Executive VP & Treasurer
Mr. Michael J. Lane	Executive VP and GM of Reference Laboratories & Information Technology
Mr. John Hart	Senior Vice President of Global Operations
Mr. Jeffery D. Chadbourne	Senior Vice President of Commercial Finance & Sales Operations
Dr. Martin Smith Ph.D.	Executive VP & CTO
Mr. Ken Grady	Senior VP & Chief Information Officer
Ms. Sharon E. Underberg J.D.	Executive VP, General Counsel, & Corporate Secretary
Mr. Michael P. Johnson	Executive VP & Chief Human Resources Officer
Mr. George J. Fennell	Senior VP & Chief Revenue Officer

Important FAQs about investing in Idexx Laboratories from India :

What is Idexx Laboratories share price today?

Idexx Laboratories (IDXX) share price today is $444.72.

Can Indians buy Idexx Laboratories shares?

Yes, Indians can invest in the Idexx Laboratories (IDXX) from India.

With INDmoney, you can buy Idexx Laboratories at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Idexx Laboratories at zero transaction cost.

How can I buy Idexx Laboratories shares from India?

It is very easy to buy Idexx Laboratories from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Idexx Laboratories be purchased?

Yes, you can buy fractional shares of Idexx Laboratories with INDmoney app.

What are the documents required to start investing in Idexx Laboratories stocks?

To start investing in Idexx Laboratories, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.